A. Bodurtha

1.0k total citations
23 papers, 763 citations indexed

About

A. Bodurtha is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, A. Bodurtha has authored 23 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in A. Bodurtha's work include Melanoma and MAPK Pathways (5 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). A. Bodurtha is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). A. Bodurtha collaborates with scholars based in Canada, United States and New Zealand. A. Bodurtha's co-authors include Noreen M. Walsh, S. T. Norvell, A. S. Macdonald, A. Guclu, Michael J. Mastrangelo, T. Ghose, Ian Quirt, Donald P. Cameron, Darwin O. Chee and H. Silver and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. Bodurtha

23 papers receiving 694 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Bodurtha Canada 15 376 256 222 173 90 23 763
J.H. Holzner Austria 16 364 1.0× 100 0.4× 292 1.3× 187 1.1× 178 2.0× 49 858
S Riedl Germany 12 341 0.9× 250 1.0× 397 1.8× 52 0.3× 103 1.1× 20 966
Teruo Sasatomi Japan 15 444 1.2× 394 1.5× 290 1.3× 62 0.4× 58 0.6× 41 785
Takehiro Nohara Japan 11 389 1.0× 192 0.8× 351 1.6× 72 0.4× 156 1.7× 25 784
James G. Jakowatz United States 16 602 1.6× 268 1.0× 342 1.5× 145 0.8× 75 0.8× 44 948
Uhi Toh Japan 18 407 1.1× 312 1.2× 267 1.2× 106 0.6× 149 1.7× 79 1.1k
Masafumi Takimoto Japan 13 402 1.1× 120 0.5× 213 1.0× 40 0.2× 67 0.7× 40 815
Sangeetha M. Reddy United States 15 499 1.3× 248 1.0× 256 1.2× 79 0.5× 169 1.9× 29 830
Claudius Rudin United Kingdom 7 532 1.4× 65 0.3× 352 1.6× 92 0.5× 60 0.7× 16 845
Brandon G. Smaglo United States 15 368 1.0× 89 0.3× 223 1.0× 74 0.4× 108 1.2× 54 686

Countries citing papers authored by A. Bodurtha

Since Specialization
Citations

This map shows the geographic impact of A. Bodurtha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bodurtha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bodurtha more than expected).

Fields of papers citing papers by A. Bodurtha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bodurtha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bodurtha. The network helps show where A. Bodurtha may publish in the future.

Co-authorship network of co-authors of A. Bodurtha

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bodurtha. A scholar is included among the top collaborators of A. Bodurtha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bodurtha. A. Bodurtha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quirt, Ian, A. Bodurtha, Reinhard Lohmann, et al.. (2002). Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 20(4). 431–437. 35 indexed citations
2.
McCready, David R., A. Bodurtha, Noelle Davis, et al.. (1999). Sentinel lymph-node biopsy in breast cancer.. Europe PMC (PubMed Central). 42(6). 406–7. 9 indexed citations
3.
4.
5.
Knowling, Margaret A., et al.. (1994). Phase II trial of 10-EDAM in advanced soft tissue sarcoma. Annals of Oncology. 5(8). 766–768. 7 indexed citations
6.
Verma, Sunil, Ian Quirt, E. Eisenhauer, et al.. (1993). A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma. Annals of Oncology. 4(3). 254–255. 7 indexed citations
7.
Morris, John, et al.. (1992). Isolation of Klebsiella Pneumoniae from an Hepatic Inflammatory Pseudotumour. Canadian Journal of Gastroenterology and Hepatology. 6(2). 84–86. 10 indexed citations
8.
9.
Iscoe, Neill, Elizabeth A. Eisenhauer, & A. Bodurtha. (1990). Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study. Investigational New Drugs. 8(1). 121–123. 5 indexed citations
10.
Walsh, Noreen M. & A. Bodurtha. (1990). Auerbach's myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen's neurofibromatosis.. PubMed. 114(5). 522–5. 52 indexed citations
11.
Pounder, Derrick J., et al.. (1988). Prognostic factors in colorectal carcinoma of young adults.. Canadian Journal of Surgery. 31(3). 150–3. 47 indexed citations
12.
Shelley, W, Ian Quirt, A. Bodurtha, et al.. (1985). Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.. PubMed. 69(9). 941–4. 3 indexed citations
13.
Eisenhauer, Elizabeth A., Ian G. Kerr, A. Bodurtha, et al.. (1985). A phase II study of spirogermanium in patients with metastatic malignant melanoma. Investigational New Drugs. 3(3). 303–305. 5 indexed citations
14.
Bodurtha, A., et al.. (1977). A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 40(5). 2091–2093. 32 indexed citations
15.
Ghose, T. K., J. Tai, A. Guclu, et al.. (1976). ANTIBODIES AS CARRIERS OF RADIONUCLIDES AND CYTOTOXIC DRUGS IN THE TREATMENT AND DIAGNOSIS OF CANCER. Annals of the New York Academy of Sciences. 277(1). 671–689. 16 indexed citations
16.
17.
Berkelhammer, Jane, et al.. (1975). Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. International Journal of Cancer. 16(4). 571–578. 20 indexed citations
18.
Bodurtha, A., et al.. (1974). Hepatic Granulomas and Other Hepatic Lesions Associated with BCG Immunotherapy for Cancer. American Journal of Clinical Pathology. 61(6). 747–752. 26 indexed citations
19.
Chee, Darwin O. & A. Bodurtha. (1974). Facilitation and inhibition of B16 melanoma by BCG in vivo and by lymphoid cells from BCG‐treated mice in vitro. International Journal of Cancer. 14(1). 137–143. 37 indexed citations
20.
Ghose, T., S. T. Norvell, A. Guclu, et al.. (1972). Immunochemotherapy of Cancer with Chlorambucil-carrying Antibody. BMJ. 3(5825). 495–499. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.H. Holzner Breakdown of academic impact, for papers by S Riedl Breakdown of academic impact, for papers by Teruo Sasatomi Breakdown of academic impact, for papers by Takehiro Nohara Breakdown of academic impact, for papers by James G. Jakowatz Breakdown of academic impact, for papers by Uhi Toh Breakdown of academic impact, for papers by Masafumi Takimoto Breakdown of academic impact, for papers by Sangeetha M. Reddy Breakdown of academic impact, for papers by Claudius Rudin Breakdown of academic impact, for papers by Brandon G. Smaglo
Rankless by CCL
2026